Related Experiment Video

Updated: Sep 30, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

[New oral antidiabetic agents and current strategies of peroral antidiabetic therapy (PAD)]

J Rybka1, M Kvapil

  • 1Interní klinika IPVZ Praha se sídlem v Bat'ovĕ nemocnici, Zlín.

Vnitrni Lekarstvi
|July 23, 2002
PubMed

Insights

Optimizing type 2 diabetes treatment requires personalized therapy based on disease stage and key disorders. New strategies are needed due to the limited effectiveness of current oral antidiabetic medications.

Area of Science:

  • Endocrinology
  • Pharmacology

Context:

  • Type 2 diabetes mellitus (T2DM) management necessitates individualized therapeutic approaches.
  • Current treatment strategies for T2DM exhibit suboptimal effectiveness in many patients.
  • Understanding the interplay of pathophysiological disorders is crucial for effective T2DM compensation.

Purpose:

  • To explore novel therapeutic strategies for optimizing type 2 diabetes management.
  • To investigate the potential of existing oral antidiabetic agents and new substances for improved T2DM control.

Summary:

  • Effective management of type 2 diabetes depends on tailoring treatments to individual disease progression and the specific balance of pathophysiological mechanisms.
  • The search for more effective therapies is driven by the inadequate outcomes associated with current treatment protocols.
  • Research efforts are directed towards both refining the use of established oral antidiabetic drugs and introducing novel pharmacological agents.

Impact:

  • This research aims to improve glycemic control and patient outcomes in type 2 diabetes.
  • Developing more effective antidiabetic therapies can reduce the long-term complications associated with poorly managed T2DM.
  • Advancements in T2DM treatment can lead to a more personalized and efficient healthcare approach for affected individuals.

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...